Di Lorenzo Giuseppe, Konstantinopoulos Panagiotis A, Pantanowitz Liron, Di Trolio Rossella, De Placido Sabino, Dezube Bruce J
Department of Molecular and Clinical Endocrinology and Oncology, University of Federico II, Naples, Italy.
Lancet Oncol. 2007 Feb;8(2):167-76. doi: 10.1016/S1470-2045(07)70036-0.
The advent of highly active antiretroviral therapy (HAART) has lead to a substantial reduction in the prevalence, morbidity, and mortality associated with AIDS-related Kaposi's sarcoma. Similarly, concomitant advances in chemotherapy and supportive-care protocols have allowed for Kaposi's sarcoma to be managed more effectively in comparison with the pre-HAART era. Furthermore, developments in our understanding of the pathogenesis of Kaposi's sarcoma have identified several molecular targets that can potentially provide new therapeutic strategies. This Review discusses the role of conventional chemotherapeutic and immunomodulatory agents in the treatment of Kaposi's sarcoma and summarises the current status and future prospects of novel molecularly targeted agents in the treatment of this disease.
高效抗逆转录病毒疗法（HAART）的出现已使与艾滋病相关的卡波西肉瘤的患病率、发病率和死亡率大幅降低。同样，化疗和支持治疗方案的同步进展使得卡波西肉瘤相比HAART时代之前能得到更有效的管理。此外，我们对卡波西肉瘤发病机制认识的进展已确定了几个可能提供新治疗策略的分子靶点。本综述讨论了传统化疗药物和免疫调节药物在卡波西肉瘤治疗中的作用，并总结了新型分子靶向药物在该疾病治疗中的现状和未来前景。
